US 11,851,496 B2
Antibodies against the human fshr extracellular domain
Nicolae Ghinea, Paris (FR)
Assigned to FSHR THERANOSTICS SAS, Paris (FR)
Filed by INSERM—INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, Paris (FR); and INSTITUT CURIE, Paris (FR)
Filed on Dec. 9, 2020, as Appl. No. 17/116,115.
Application 17/116,115 is a division of application No. 16/494,891, granted, now 10,927,179, previously published as PCT/EP2018/055613, filed on Mar. 7, 2018.
Claims priority of application No. 17305302 (EP), filed on Mar. 20, 2017.
Prior Publication US 2021/0130481 A1, May 6, 2021
Int. Cl. C07K 16/28 (2006.01); G01N 33/574 (2006.01)
CPC C07K 16/2869 (2013.01) [G01N 33/57415 (2013.01); G01N 33/57434 (2013.01); C07K 2317/565 (2013.01); G01N 2333/726 (2013.01)] 12 Claims
 
1. An isolated nucleic acid that encodes an antibody or antigen-binding portion thereof directed against the human follicle-stimulating hormone receptor (FSHR), the antibody or antigen-binding portion thereof comprising the following:
a variable heavy (VH) chain complementarity determining region (CDR)1 having the amino acid sequence SEQ ID NO: 16, wherein Xa is Q, R or K; Xb is F, Q, S or Y, Xc is Y or W, Xd is V, L, I or T, and Xe is G, I, L, Q or T,
a variable heavy (VH) chain complementarity determining region (CDR)2 having the amino acid sequence SEQ ID NO: 11, wherein Xf is F, L or Y, Xg is R or Q, Xh T or N and Xi G or Q,
a variable heavy (VH) chain complementarity determining region (CDR)3 having the amino acid sequence SEQ ID NO: 12,
a variable light chain (VL) complementarity determining region (CDR)1 having the amino acid sequence SEQ ID NO: 13,
a variable light chain (VL) complementarity determining region (CDR)2 having the amino acid sequence SEQ ID NO: 14, or
a variable light chain (VL) complementarity determining region (CDR)3 having the amino acid sequence SEQ ID NO: 15.